IM156 on Fast Track as IPF Treatment

IM156 on Fast Track as IPF Treatment

293619

IM156 on Fast Track as IPF Treatment

The U.S. Food and Drug Administration (FDA) granted fast track status to IM156, ImmunoMet Therapeutics’ treatment candidate for idiopathic pulmonary fibrosis (IPF). “Fast track designation is another important milestone for ImmunoMet with the potential to speed our ability to advance IM156 to patients,” Benjamin Cowen PhD, ImmunoMet’s CEO, said in a press release. Fast-tracked compounds may move faster through development and review phases. The designation is given to potential medications developed to treat serious conditions…

You must be logged in to read/download the full post.